Skip to content

Maclizumab Dexamethasone - a CD163 Targeting Antibody Drug Conjugate directed Macrophages for Treatment of NASH and AAH

The novel ADC inhibits NASH progression in terms of ballooning, fat accumulation and fibrosis

Published: 25th June 2019
Maclizumab Dexamethasone - a CD163 Targeting Antibody Drug Conjugate directed Macrophages for Treatment of NASH and AAH
yodiyim, stock.adobe.com
Patents
  • Intellectual property rights are hold by three patent families (WO2011039510, WO2011039511, WO2002032941).
IP Status
  • Patent application submitted
Seeking
  • Development partner
  • Commercial partner
  • Seeking investment